YIRUI Pharmaceutical Technology, the biotech firm developing small molecule drugs for serious diseases, has closed a $14.7M Series A funding round. Founded in June 2018, YIRUI focuses on identifying and optimizing lead compounds against first-in-class targets, showing high therapeutic potential for chronic skin diseases, autoimmune disorders, and diabetes complications.
The company, which describes itself as being in a period of rapid growth, leverages an experienced team of pharmaceutical scientists, physicians, and executives. Its mission is to bring safe, effective, and affordable drugs to patients with urgent unmet medical needs.















